1
|
Cuñat O, Del Hoyo-Buxo B, Vila-Badia R, Serra-Arumí C, Butjosa A, Del Cacho N, Colomer-Salvans A, Dolz M, Cuevas-Esteban J, Iglesias-González M, Usall J, Profep Group. Negative symptoms in drug-naive patients with a first-episode psychosis (FEP). Asian J Psychiatr 2023; 81:103448. [PMID: 36652842 DOI: 10.1016/j.ajp.2023.103448] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/04/2022] [Revised: 01/02/2023] [Accepted: 01/02/2023] [Indexed: 01/07/2023]
Abstract
INTRODUCTION Negative symptoms are nuclear features of schizophrenia that may be present from the onset of the disease. In recent years, it has been described 2 subdomains of negative symptoms: experiential and expressive deficits. The aim of the study is to examine the relationship between negative symptoms and demographic and clinical variables in patients with first-episode psychosis. Also, to explore whether there are differences in the association among these variables and negative symptoms when divided into both subdomains. MATERIAL AND METHODS A cross-sectional study was performed in 160 patients (52 females and 108 males) with a diagnosis of a first episode psychosis. A questionnaire was administered to collect demographic and clinical variables. RESULTS A backward stepwise linear regressions analysis was performed in order to observe potential associations between demographic and clinical variables and the presence of negative symptoms. All three models are predicted by worse PSP score, a higher CDSS, a higher disorganized factor score and a lower excited factor score. A longer duration of untreated psychosis (DUP) is associated to a higher score in the experiential deficit subdomain only. CONCLUSIONS Our work highlights some clinical and phenomenological differences between experiential and expressive deficits. We think that taking into account both subdomains in future studies may lead to more accurate clinical assessment and interventions.
Collapse
Affiliation(s)
- O Cuñat
- Parc Sanitari Sant Joan de Déu, CIBERSAM, Doctor Antoni Pujadas, Sant Boi de Llobregat, Spain.
| | - B Del Hoyo-Buxo
- Parc Sanitari Sant Joan de Déu, CIBERSAM, Doctor Antoni Pujadas, Sant Boi de Llobregat, Spain
| | - R Vila-Badia
- Parc Sanitari Sant Joan de Déu, CIBERSAM, Doctor Antoni Pujadas, Sant Boi de Llobregat, Spain; Etiopatogènia i tractament dels trastorns mentals greus (MERITT), Institut de Recerca Sant Joan de Déu, Esplugues de Llobregat, Spain
| | - C Serra-Arumí
- Parc Sanitari Sant Joan de Déu, CIBERSAM, Doctor Antoni Pujadas, Sant Boi de Llobregat, Spain; Etiopatogènia i tractament dels trastorns mentals greus (MERITT), Institut de Recerca Sant Joan de Déu, Esplugues de Llobregat, Spain
| | - A Butjosa
- Parc Sanitari Sant Joan de Déu, CIBERSAM, Doctor Antoni Pujadas, Sant Boi de Llobregat, Spain; Hospital Infanto-juvenil Sant Joan de Déu, Institut de Recerca Sant Joan de Déu, CIBERSAM, Esplugues de Llobregat, Spain
| | - N Del Cacho
- Parc Sanitari Sant Joan de Déu, CIBERSAM, Doctor Antoni Pujadas, Sant Boi de Llobregat, Spain; Etiopatogènia i tractament dels trastorns mentals greus (MERITT), Institut de Recerca Sant Joan de Déu, Esplugues de Llobregat, Spain
| | - A Colomer-Salvans
- Parc Sanitari Sant Joan de Déu, CIBERSAM, Doctor Antoni Pujadas, Sant Boi de Llobregat, Spain; Etiopatogènia i tractament dels trastorns mentals greus (MERITT), Institut de Recerca Sant Joan de Déu, Esplugues de Llobregat, Spain
| | - M Dolz
- Hospital Infanto-juvenil Sant Joan de Déu, Institut de Recerca Sant Joan de Déu, CIBERSAM, Esplugues de Llobregat, Spain
| | - J Cuevas-Esteban
- Hospital Universitari Germans Trias i Pujol, CIBERSAM, Badalona, Spain; Universitat Autònoma de Barcelona, Cerdanyola del Vallès, Spain
| | - M Iglesias-González
- Hospital Universitari Germans Trias i Pujol, CIBERSAM, Badalona, Spain; Universitat Autònoma de Barcelona, Cerdanyola del Vallès, Spain
| | - J Usall
- Parc Sanitari Sant Joan de Déu, CIBERSAM, Doctor Antoni Pujadas, Sant Boi de Llobregat, Spain; Etiopatogènia i tractament dels trastorns mentals greus (MERITT), Institut de Recerca Sant Joan de Déu, Esplugues de Llobregat, Spain
| | - Profep Group
- Parc Sanitari Sant Joan de Déu, CIBERSAM, Doctor Antoni Pujadas, Sant Boi de Llobregat, Spain; Etiopatogènia i tractament dels trastorns mentals greus (MERITT), Institut de Recerca Sant Joan de Déu, Esplugues de Llobregat, Spain
| |
Collapse
|
2
|
Vila-Payeras A, Iglesias-González M, Terrasa-Sagristá F, Parera-Amer E. Cutaneous ulcer with thrombogenic vasculopathy in a patient receiving bevacizumab. Indian J Dermatol Venereol Leprol 2021; 87:268-270. [PMID: 33769753 DOI: 10.25259/ijdvl_398_20] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2020] [Accepted: 09/01/2020] [Indexed: 11/04/2022]
Affiliation(s)
- Aina Vila-Payeras
- Department of Dermatology, Son Llàtzer Hospital, Palma de Mallorca, Spain
| | | | | | | |
Collapse
|
3
|
Iglesias-González M, Gil-Girbau M, Peñarrubia-María MT, Blanco-García E, Fernández-Vergel R, Serrano-Blanco A, Carbonell-Duacastella C, Alonso J, Rubio-Valera M. Barriers and opportunities for the treatment of mild-to-moderate depression with a watchful waiting approach. Patient Educ Couns 2021; 104:611-619. [PMID: 32782178 DOI: 10.1016/j.pec.2020.07.013] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/28/2020] [Revised: 06/17/2020] [Accepted: 07/16/2020] [Indexed: 06/11/2023]
Abstract
OBJECTIVE The aim of this study is to explore barriers and opportunities in non-pharmacological treatment of depression in primary care (PC) from the perspective of family physicians (FPs). METHODS Qualitative analysis was used to explore a sample of 36 FPs treating patients with depressive symptoms. Criteria to maximize variability were followed. Participants were identified by key informants. Six group interviews were developed following a semi-structured thematic script. All interviews were transcribed, analyzed and triangulated. Information was saturated. Principals of reflexivity and circularity were implemented. RESULTS The results obtained followed 3 main theoretical axes: the FP, the patient, the healthcare system, and the interaction between them. Barriers included poor alignment with clinical practice guidelines, inadequate FP training, patients' preferences and structural challenges in PC. Among opportunities were good FP clinical interview skills, the beneficial bond of trust between patients and FPs and improved communication with mental healthcare services. CONCLUSION Based on FPs' perceptions, non-pharmacological treatment of depression in PC is particularly limited by lack of structured training; patients' preferences and treatment expectations; structural challenges in PC; and insufficient support from specialized mental health professionals. PRACTICE IMPLICATIONS Resources for education, structural support in PC and modified back up from mental healthcare services are needed.
Collapse
Affiliation(s)
- M Iglesias-González
- Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública, CIBERESP, Madrid, Spain; Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
| | - M Gil-Girbau
- Teaching, Research & Innovation Unit, Institut de Recerca Sant Joan de Déu, Esplugues de Llobregat, Spain; Primary Care Prevention and Health Promotion Research Network (redIAPP), Barcelona, Spain
| | - M T Peñarrubia-María
- Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública, CIBERESP, Madrid, Spain; Fundació Idiap Jordi Gol i Gurina, Barcelona, Spain; SAP Delta Llobregat, DAP Costa Ponent, Institut Català de la Salut (ICS), Catalonia, Spain
| | - E Blanco-García
- Fundació Idiap Jordi Gol i Gurina, Barcelona, Spain; SAP Delta Llobregat, DAP Costa Ponent, Institut Català de la Salut (ICS), Catalonia, Spain
| | - R Fernández-Vergel
- Primary Care Prevention and Health Promotion Research Network (redIAPP), Barcelona, Spain; Fundació Idiap Jordi Gol i Gurina, Barcelona, Spain; SAP Delta Llobregat, DAP Costa Ponent, Institut Català de la Salut (ICS), Catalonia, Spain
| | - A Serrano-Blanco
- Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública, CIBERESP, Madrid, Spain; Parc Sanitari Sant Joan de Déu, Sant Boi de Llobregat, Barcelona, Spain
| | - C Carbonell-Duacastella
- Teaching, Research & Innovation Unit, Institut de Recerca Sant Joan de Déu, Esplugues de Llobregat, Spain
| | - J Alonso
- Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública, CIBERESP, Madrid, Spain; Health Services Research Unit, IMIM-Hospital del Mar Medical Research Institute, Barcelona, Spain; Pompeu Fabra University (UPF), Barcelona, Spain
| | - M Rubio-Valera
- Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública, CIBERESP, Madrid, Spain; Teaching, Research & Innovation Unit, Institut de Recerca Sant Joan de Déu, Esplugues de Llobregat, Spain.
| |
Collapse
|
4
|
Aznar-Lou I, Iglesias-González M, Gil-Girbau M, Serrano-Blanco A, Fernández A, Peñarrubia-María MT, Sabés-Figuera R, Murrugarra-Centurión AG, March-Pujol M, Bolívar-Prados M, Rubio-Valera M. Corrigendum to "Impact of initial medication non-adherence to SSRIs on medical visits and sick leaves" [J Affect Disord. 2018 Jan 15;226:282-286]. J Affect Disord 2020; 261:110. [PMID: 31610310 DOI: 10.1016/j.jad.2019.09.086] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Affiliation(s)
- Ignacio Aznar-Lou
- Teaching, Research & Innovation Unit, Institut de Recerca Sant Joan de Déu, Esplugues de Llobregat, Spain; Centro de Investigación Biomédica en Red en Epidemiología y Salud Pública, CIBERESP, Madrid, Spain; School of Pharmacy, University of Barcelona, Barcelona, Spain
| | | | - Montserrat Gil-Girbau
- Teaching, Research & Innovation Unit, Institut de Recerca Sant Joan de Déu, Esplugues de Llobregat, Spain; School of Pharmacy, University of Barcelona, Barcelona, Spain; Primary Care Prevention and Health Promotion Research Network (redIAPP), Spain
| | - Antoni Serrano-Blanco
- Centro de Investigación Biomédica en Red en Epidemiología y Salud Pública, CIBERESP, Madrid, Spain; Parc Sanitari Sant Joan de Déu, University of Barcelona, Sant Boi de Llobregat, Spain
| | - Ana Fernández
- Centro de Investigación Biomédica en Red en Epidemiología y Salud Pública, CIBERESP, Madrid, Spain; Community Health Service, Public Health Agency of Barcelona, Barcelona, Spain
| | - María Teresa Peñarrubia-María
- Centro de Investigación Biomédica en Red en Epidemiología y Salud Pública, CIBERESP, Madrid, Spain; Fundació Idiap Jordi Gol i Gurina, Barcelona, Spain
| | - Ramón Sabés-Figuera
- Centro de Investigación Biomédica en Red en Epidemiología y Salud Pública, CIBERESP, Madrid, Spain; Faculty of Economic and Business Science, Universitat Pompeu Fabra, Barcelona, Spain
| | | | - Marian March-Pujol
- Centro de Investigación Biomédica en Red en Epidemiología y Salud Pública, CIBERESP, Madrid, Spain; School of Pharmacy, University of Barcelona, Barcelona, Spain
| | | | - Maria Rubio-Valera
- Teaching, Research & Innovation Unit, Institut de Recerca Sant Joan de Déu, Esplugues de Llobregat, Spain; Centro de Investigación Biomédica en Red en Epidemiología y Salud Pública, CIBERESP, Madrid, Spain; School of Pharmacy, University of Barcelona, Barcelona, Spain.
| |
Collapse
|
5
|
Robles-Martínez M, Monge MF, Iglesias-González M. Cyclosporine-Olanzapine Drug-Drug Interaction. Prim Care Companion CNS Disord 2018; 20. [DOI: 10.4088/pcc.17l02124] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022] Open
|
6
|
Aznar-Lou I, Iglesias-González M, Gil-Girbau M, Serrano-Blanco A, Fernández A, Peñarrubia-María MT, Sabés-Figuera R, Murrugarra-Centurión AG, March-Pujol M, Bolívar-Prados M, Rubio-Valera M. Impact of initial medication non-adherence to SSRIs on medical visits and sick leaves. J Affect Disord 2018; 226:282-286. [PMID: 29024901 DOI: 10.1016/j.jad.2017.09.057] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/02/2017] [Revised: 05/30/2017] [Accepted: 09/29/2017] [Indexed: 10/18/2022]
Abstract
BACKGROUND Initial medication non-adherence (IMNA) to antidepressants, which are commonly used to treat depression in primary care (PC), is around 6-12%. Although it is well known that post-initial non-adherence to antidepressants increases the cost of depression, the impact of IMNA on cost is unknown. The aim of this study is to assess the impact of IMNA to Selective Serotonin Reuptake Inhibitors (SSRI) on medical visits and sick leave in patients with depression treated in PC in Catalonia (Spain). METHODS This was a four-year retrospective register-based study (2011-2014). All PC patients of working age who received a new SSRI prescription and had a diagnosis of depression were included (N = 79,642). Treatment initiation, number of visits and days on sick leave were gathered from the database. We assessed the impact of IMNA on costs with ordered logistic regressions. RESULTS The 3-year incidence of IMNA was 15%. Initially non-adherent patients made a lesser number of GP visits (OR = 0.82; 95% CI = 0.79-0.84) but had more days on sick leave (OR = 1.25; 95% CI = 1.20-1.31). There were no differences in the number of specialist visits (OR = 1.04; 95% CI = 0.99-1.08). LIMITATIONS Differences between adherent and non-adherent patients could be explained by non-observed variables. GP recognition and documentation of depression might be inaccurate. Costs of unpaid work and use of hospital services were not considered. CONCLUSIONS Although IMNA decreases the use of medical PC services, it increases the number of days on sick leave. This could also indicate worse health status. These consequences are currently overlooked when considering post-initial medication non-adherence.
Collapse
Affiliation(s)
- Ignacio Aznar-Lou
- Teaching, Research & Innovation Unit, Institut de Recerca Sant Joan de Déu, Esplugues de Llobregat, Spain; Centro de Investigación Biomédica en Red en Epidemiología y Salud Pública, CIBERESP, Madrid, Spain; School of Pharmacy, University of Barcelona, Barcelona, Spain
| | | | - Montserrat Gil-Girbau
- Teaching, Research & Innovation Unit, Institut de Recerca Sant Joan de Déu, Esplugues de Llobregat, Spain; School of Pharmacy, University of Barcelona, Barcelona, Spain; Primary Care Prevention and Health Promotion Research Network (redIAPP), Spain
| | - Antoni Serrano-Blanco
- Centro de Investigación Biomédica en Red en Epidemiología y Salud Pública, CIBERESP, Madrid, Spain; Parc Sanitari Sant Joan de Déu, University of Barcelona, Sant Boi de Llobregat, Spain
| | - Ana Fernández
- Centro de Investigación Biomédica en Red en Epidemiología y Salud Pública, CIBERESP, Madrid, Spain; Community Health Service, Public Health Agency of Barcelona, Barcelona, Spain
| | - María Teresa Peñarrubia-María
- Centro de Investigación Biomédica en Red en Epidemiología y Salud Pública, CIBERESP, Madrid, Spain; Fundació Idiap Jordi Gol i Gurina, Barcelona, Spain
| | - Ramón Sabés-Figuera
- Centro de Investigación Biomédica en Red en Epidemiología y Salud Pública, CIBERESP, Madrid, Spain; Faculty of Economic and Business Science, Universitat Pompeu Fabra, Barcelona, Spain
| | | | - Marian March-Pujol
- Centro de Investigación Biomédica en Red en Epidemiología y Salud Pública, CIBERESP, Madrid, Spain; School of Pharmacy, University of Barcelona, Barcelona, Spain
| | | | - Maria Rubio-Valera
- Teaching, Research & Innovation Unit, Institut de Recerca Sant Joan de Déu, Esplugues de Llobregat, Spain; Centro de Investigación Biomédica en Red en Epidemiología y Salud Pública, CIBERESP, Madrid, Spain; School of Pharmacy, University of Barcelona, Barcelona, Spain.
| |
Collapse
|